Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad, Quest Diagnostics, Ferrer in Code, Agendia, Qiagen, Digene, Affymetrix, Wisconsin Institute, Hyderabad, Lipomics, UCSD, Third Wave, Labcorp, George Mason University

Premium
Quest to Outfit Labs With Bio-Rad's BioPlex 2200 Platform, HIV Assay
 
Bio-Rad Laboratories this week said it will supply Quest Diagnostics with its BioPlex 2200 systems and autoimmune test reagents, as well as its HIV-1/HIV-2 PLUS O EIA assay for use in its reference laboratories nationwide.
 
Terms of the agreements were not released.
 
In early April Bio-Rad announced that it had released Epstein Barr virus kits to run on the BioPlex 2200 system and that it has more than 15 other multiplex reagent kits in development.
 

 
Ferrer Unit to Distribute Agendia's MammaPrint, CupPrint Dxs in Spain
 
Ferrer in Code will distribute Agendia’s MammaPrint breast cancer recurrence assay and its CupPrint cancer of unknown primary test in Spain, Agendia said this week.
 
Agendia CEO Bernhard Sixt said the partners are currently discussing “future steps in order to intensify the co-operation in other parts of the world.”
 
Ferrer in Code is a subsidiary of the pharmaceutical company Ferrer.
 
Financial terms of the agreement were not released.
 

 
Qiagen's $1.6B Bid for Digene Passes Federal Waiting Period
 
Qiagen said this week that federal regulators have cleared its planned acquisition of Digene.
 
The company said the Hart-Scott-Rodino antitrust deadline passed on July 16 at midnight without a hitch, enabling the shop to buy Digene for $1.6 billion.
 
The deal is subject to the tender of a majority of Digene's common stock on a fully diluted basis before 11:59 p.m. EST on July 20, unless the offer is extended, as well as approval by Qiagen’s shareholders, among other conditions.
 
Qiagen said it expects to close the acquisition in August or September.
 

 
Affymetrix, Wisconsin Institute to Pursue Genes Linked to Childhood Diseases
 
Affymetrix and the Children’s Research Institute in Wisconsin will use Affy’s GeneChip technology to identify genetic variations linked to common, complex childhood diseases, Affy said this week.
 
CRI, a non-profit medical research arm of the Children's Hospital and Health System affiliated with the Medical College of Wisconsin, intends to use the data from the large-scale studies to develop diagnostics, and to “show the clinical utility of array-based molecular diagnostics,” Affy said. 
 
Affy is conducting the five-year partnership through its Translational Medicine Program.
 

 
Southern India Plans New Genomics Research Center
 
Hyderabad in the Southern Indian state of Andhra Pradesh will be home to a new genomics center on 75 acres of land, according to a report posted Friday on the Indian news website Andhra Café.  
 
The institute received the land at no cost from the state government and is to be funded with 3 billion rupees ($75 million). It is expected to study early disease diagnosis, gene therapy, and stem-cell treatments, according to the report.
 
It was not immediately clear when the center will be completed.
 

 
Lipomics, UCSD to Study Insulin Resistance; Lipomics to Retain Certain Dx Rights
 
Lipomics Technologies and the University of California, San Diego, plan to investigate the underlying mechanisms involved in insulin-resistance disorders.
 
Under the agreement, Lipomics and UCSD will collaborate on basic and clinical research projects to study non-insulin-dependent diabetes mellitus, obesity, and other insulin-resistance disorders, as well as studies that aim to identify the roles different organ systems play in NIDDM, the company said this week.
 
Lipomics said it will retain certain rights to develop diagnostic applications that will be based on information stemming from the studies.
 
Financial terms of the agreement have not been released.
 

 
Third Wave, Labcorp To Co-Develop Companion Dx for Arca Discovery's Heart Failure Drug
 
Third Wave Technologies said this week that it will collaborate with Laboratory Corporation of America to develop a diagnostic that may be used in conjunction with a heart failure drug that is being developed by Arca Discovery. 
 
The diagnostic is intended to help physicians determine use of the drug bucindolol, a beta blocker that Third Wave said could be "the first genetically targeted cardiovascular drug."
 
The test will be developed in tandem with the drug's approval process, the company added.
 
Bucindolol has shown "extensive" efficacy and safety in Phase III trials, Third Wave said, noting that Arca plans to use genetic data to target patients most likely to respond to the drug when it seeks FDA approval in 2008.
 
Labcorp acquired the rights to develop and commercialize the companion diagnostic for the Arca drug in February.
 
Financial terms of the agreement were not released.
 

 
George Mason CLIA Lab to Use Aushon Arrayer to Study PGx-Based Cancer Rxs
 
George Mason University will use an Aushon Biosystems 2470 arrayer to study targeted cancer treatments, the company said last week.
 
George Mason has installed the 2470 in a CAP-CLIA laboratory that focuses on clinical trials for cancer treatments based on protein expression profiles.
  
Financial terms of the agreement were not released.

Filed under